Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti (eptinezumab) in migraine prevention
Lundbeck announced that Vyepti (eptinezumab) met the primary and all key secondary endpoints in SUNRISE, a phase III pivotal trial predominantly conducted in Asia evaluating the efficacy and… read more.
